arrow
C

Christian Steidl

BC Cancer
H指数:79
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas

多中心、单臂、II期临床试验:达沙替尼在T滤泡辅助细胞淋巴瘤中的应用

2026-10-050
OAAI
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma

伊匹木单抗、纳武利尤单抗和 Brentuximab Vedotin 治疗复发霍奇金淋巴瘤的随机二期研究

Blood
IF23.1
2026-04-011
PRE
Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology

在高MYC/BCL2易位的弥漫大B细胞淋巴瘤中,进行剂量调整的EPOCH-R方案的群体推广,该淋巴瘤具有DLBCL形态。

2025-10-170
OAAI
Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma

开发和验证一种用于预测滤泡性淋巴瘤患者早期事件的基因表达谱

2025-09-220
OAAI
High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

高级别B细胞淋巴瘤,非其他特指类型:一项LLMPP研究。

2025-07-210
OAAI
Distinct follicular T cell subsets regulate lymphoma progression and outcomes

不同的滤泡性T细胞亚群调控淋巴瘤进展和结局

2025-07-030
OAAI
Somatic IRF4 mutations and thymic tropism in primary mediastinal large B-cell lymphoma

体细胞IRF4突变和胸腺趋向性在原发性纵隔大B细胞淋巴瘤中的作用

Blood
IF23.1
2025-06-240
OA
A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy

一种基于遗传学的晚期滤泡性淋巴瘤新型分类法,可识别接受 bendamustine-rituximab 免疫化疗后的预后亚组

BLOOD
IF23.1
2024-11-050
PRE
CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma

CSF2RB基因突变导致经典霍奇金淋巴瘤中细胞因子依赖性的获得性功能表型。

BLOOD
IF23.1
2024-11-050
PRE
EBV prevalence and overall survival in the MultiEthnic Study of Hodgkin lymphoma (MESH)
2024-09-210
PRE